NCT06934616View on ClinicalTrials.gov

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Solid Tumor Cancer
Interventions
DRUG

GB268

GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY